Adamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a report published on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Price Performance

Shares of NASDAQ:ADMP opened at $0.13 on Friday. The firm has a fifty day simple moving average of $0.21 and a two-hundred day simple moving average of $0.21. Adamis Pharmaceuticals has a 52 week low of $0.12 and a 52 week high of $0.68.

Institutional Investors Weigh In On Adamis Pharmaceuticals

An institutional investor recently raised its position in Adamis Pharmaceuticals stock. State Street Corp boosted its stake in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 475,373 shares of the specialty pharmaceutical company’s stock after buying an additional 55,168 shares during the period. State Street Corp owned approximately 0.32% of Adamis Pharmaceuticals worth $271,000 at the end of the most recent quarter. 8.57% of the stock is owned by hedge funds and other institutional investors.

Adamis Pharmaceuticals Company Profile

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.